Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers

Benjamin Arko-Boham, Nii Ayite Aryee, Richard Michael Blay, Ewurama Dedea Ampadu Owusu, Emmanuel Ayitey Tagoe, Eshirow-Sam Doris Shackie, Ama Boatemaa Debrah, Armah Nii Adu-Aryee
2019 Cancer Genetics  
Cancer incidence and its related mortality is rising and is currently the second leading cause of death globally. In Africa, breast and prostate cancer in females and males, respectively, are the worst globally. However, biomarkers for their early detection and prognosis are not well developed. This study sought to investigate circulating cell-free DNA (ccfDNA) integrity and its potential utility as diagnostic and/or prognostic biomarker. Circulating cell-free DNA (ccfDNA) is degraded DNA
more » ... nts released into the blood plasma. In healthy individuals, the source of ccfDNA is solely apoptosis, producing evenly sized shorter DNA fragments. In cancer patients, however, necrosis produces uneven longer cell-free DNA fragments in addition to the shorter fragments originating from apoptosis. DNA integrity, expressed as the ratio of longer fragments to total DNA, may be clinically useful for the detection of breast and prostate cancer progression.
doi:10.1016/j.cancergen.2019.04.062 pmid:31105051 fatcat:mndfnstqingqpiccggkhims53u